Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.95 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.95 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | G6PD | P11413 | 2/20 | 1.00 |
| ▸ | MPI | P34949 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL21410343 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL21846961 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL30395698 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL232473 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL5429071 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL1321033 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL4755216 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL5904190 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL8524 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| (S)Apomorphine SCHEMBL19469972 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374677-A1 | VARIOUS COMPOUNDS FOR THE TREATMENT OF NEUROFIBROMATOSIS TYPE 1 | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2024-11-14 | — | — | US | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| US-20260117282-A1 | High Throughput Cell-Based Screening For Aptamers | MEIRAGTX GENE REGULATION LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| US-20240374677-A1 | VARIOUS COMPOUNDS FOR THE TREATMENT OF NEUROFIBROMATOSIS TYPE 1 | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2024-11-14 | — | — | US | disclosed |
| US-20240180881-A1 | METHODS FOR DECREASING RESISTANCE TO CHEMOTHERAPY | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2024-06-06 | — | — | US | disclosed |
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-02-29 | — | — | US | disclosed |
| US-20230384333-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-30 | — | — | US | disclosed |
| CN-117015712-A | GPCR screening method for identifying non-magic compound | 加利福尼亚大学董事会 | 2023-11-07 | — | — | CN | disclosed |
| EP-3494229-B1 | HIGH THROUGHPUT CELL-BASED SCREENING FOR APTAMERS | MEIRAGTX UK II LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| EP-4229075-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | The Regents of the University of California (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230065720-A1 | High Throughput Cell-Based Screening for Aptamers | MeiraGTx Gene Regulation Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| WO-2022271537-A1 | COMPOSITIONS AND METHODS RELATING TO INJECTABLE MICROEMULSIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11371077-B2 | High throughput cell-based screening for aptamers | MEIRAGTX UK II LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-11369615-B2 | Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor | JICHI MEDICAL UNIVERSITY (JP) | 2022-06-28 | — | — | US | disclosed |
| WO-2022099195-A1 | OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022081631-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | SLC6A3, SLC18A2, SLC6A2 | DRD2 19/4885DRD3 78/4885DRD4 70/4885 |
| US-20260117282-A1 | High Throughput Cell-Based Screening For Aptamers | CPSF6, TIA1, UPF1 | DRD2 3373/4885DRD3 3732/4885DRD4 2813/4885 |
| US-20240180881-A1 | METHODS FOR DECREASING RESISTANCE TO CHEMOTHERAPY | BLM, RAD54L, XRCC5 | DRD2 2471/4885DRD3 3835/4885DRD4 3087/4885 |
| US-20230384333-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | HTR4, HTR6, HTR1A | DRD2 82/4885DRD3 116/4885DRD4 180/4885 |
| US-20240374677-A1 | VARIOUS COMPOUNDS FOR THE TREATMENT OF NEUROFIBROMATOSIS TYPE 1 | VHL, MYC, KEAP1 | DRD2 4856/4885DRD3 4851/4885DRD4 4825/4885 |
| US-11369615-B2 | Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor | CYP27A1, HADHA, TFAM | DRD2 4708/4885DRD3 4637/4885DRD4 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.